Financing thought … I have to confess that for awhile I was a bit bummed that Spectral was not able to take advantage of expiring warrant financing ( July , 2024's) in order to top up the coffers even further.
However, in hindsight, as we approach a new 1 year high, and we have close to $9M in the bank ( shortly after end of Q2), and a further warrant allotment pending, and a final Baxter payment pending ( post FDA ) ... it's better to have avoided another 10 million share dilution at fifty-ish cents.
And any additional funds that may be required ( if any) likely would be raised with a much higher SP ( read less dilution)
MM